Pfizer Pays $11.6 Billion for Drug-Maker in Its Biggest Deal Since 2016 Pfizer announced it will buy migraine drug maker Biohaven for about $11.6 billion – in cash.

By Madeline Garfinkle

In its biggest deal since 2016, Pfizer announced on Tuesday it will buy the drug-maker Biohaven Pharmaceutical Holding for $11.6 billion, bolstering its portfolio ahead of patent losses from some cancer drugs.

The deal will give Pfizer access to Biohaven's approved drug Rimegepant, positioning it as a strong competitor in a crowded market: migraine treatments. Approved in 2020, Rimegepant treats acute migraine attacks and prevents migraine episodes — bringing in sales of $462.5 million in 2021.

This isn't the only billion-dollar deal made by Pfizer in the past year — it's just the biggest. Last year, the company bought Canadian drug developer Trillium Therapeutics for $2.26 billion and drug developer Arena Pharmaceuticals for $6.7 billion.

Related: Pfizer Stock is Ready to be Added to Your Portfolio

Although the company saw tremendous gains from its Covid-19 vaccine, Pfizer expects sales to drop from last year's highs, along with top-selling patents nearing expiration, which could account for the billions of spending on deals to maintain a strong portfolio.

"Investors will like this deal. Given Pfizer's strong balance sheet, this is still a small acquisition, and we would expect more such deals," Wells Fargo analyst Mohit Bansal said in a note.

Pfizer will acquire all the outstanding shares of Biohaven that it does not already own for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price on Monday.

Related: Buy Pfizer Before the Smart Money Catches On to the Plot

Madeline Garfinkle

Entrepreneur Staff

News Writer

Madeline Garfinkle is a News Writer at She is a graduate from Syracuse University, and received an MFA from Columbia University. 

Editor's Pick

Related Topics

Business News

Can't Find a Place on Airbnb? The New 'Black Market' Has You Covered.

Tightening regulations on short-term rentals in NYC has led to a shadow market for Airbnb alternatives.

Growing a Business

More Than 90% of Startups Don't Make It. This CEO Reveals What It Takes to Not Only Survive — But Thrive.

Learn what it takes to grow a company while also scaling as a leader.


5 Scrappy Ways to Create Quick Marketing Wins

Marketers are under pressure to create both short-term and long-term successes. Here's how you can create quick wins easily alongside your bigger strategy.

Starting a Business

How Business Community Is Making CEO Life Less Ghastly

People are starting to notice that if you want to get the best out of entrepreneurs, you have to support them. But how?

Business News

A Woman Is Suing a Popular Salad Chain After Allegedly Finding a 'Chopped' Human Finger in Her Bowl

The incident allegedly occurred at a Chop't location in Mount Kisco, New York, on April 7, 2023.

Business News

Mac Without Cheese? Kraft's Newest Product Is Going Vegan

Kraft is releasing a plant-based version of its iconic Mac & Cheese called "NotMac&Cheese."